Skip to main content
Caplight Logo









Monod Bio

Monod Bio

Private
Seattle, WashingtonHealthcare & Life Scienceshttps://monod.bio/

Last Round

Grant

Oct 15, 2025

Total Funding Raised

$27.25M

Company Overview

Monod Bio is a biotechnology company that develops AI-powered de novo protein binders and biosensors for research and diagnostic applications.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Sensors, Drug Discovery

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting

AI Layer

Application

Keywords

de novo proteinbiosensorsprotein designAI-driven protein designin silico protein designmolecular biosensorsrecombinant proteinsluciferasediagnostic reagentsin vitro diagnosticsIVDresearch use onlyRUOprotein engineeringsynthetic biologysynbio

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Monod Bio Comparables

Compare Monod Bio with similar companies based on industry and business-model similarity.

Monod Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Tierra Biosciences
70%
A-Alpha Bio
64%
Gator Bio
63%

Monod Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantOct 15, 2025
GrantSep 3, 2025
SeedAug 15, 2022

Key People

Founding team and executive leadership

Daniel-Adriano S.

CEO And President

Executive Team

Monod Bio Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 26, 2026

    Robert J. Bujarski appointed to the Board of Directors.

  • Dec 3, 2025

    Integrated with Gator Bio for next-generation biosensing capabilities.

Recent news

Latest coverage and updates

  • licenses_technologyOct 8, 2026

    On Oct 8th '26, Monod Bio, Inc. licenses its LuxSit Pro luciferase and NovoBody binding proteins non-exclusively to BPS Bioscience, Inc. in Washington and California for integration into future research products and services.

  • integrates_withAug 26, 2026

    Monod Bio, Inc. integrated with SignalChem Biotech Inc. on Aug 26th '26.

Monod Bio Filings

Explore SEC and related filing metadata, where available.

Monod Bio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Monod Bio's valuation, stock price, and market status.

Is Monod Bio a public or private company?

Monod Bio is a private company.

What is the current stock price of Monod Bio?

Monod Bio is a private company, so its shares have no public market price. Caplight tracks Monod Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is Monod Bio worth (valuation)?

Valuation information for Monod Bio is not publicly available.

Can I buy Monod Bio stock?

Monod Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was Monod Bio's last funding round?

Monod Bio's most recent funding round was Grant on October 15, 2025.

Who are the main investors in Monod Bio?

Key investors in Monod Bio include Boom Capital Ventures, Boom Capital, Gates Family Foundation, Gates Foundation, Pack Ventures.

Will Monod Bio IPO soon?

No public IPO plans have been announced for Monod Bio.

How can I track Monod Bio secondary market activity?

Caplight tracks bids, offers, and trades in Monod Bio's shares on secondary markets.

Firmographic Details

HeadquartersSeattle, Washington
Employee Range23
Year Founded2021
Last FundingOct 15, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?